Omeros, BioMed sign new 15-year lease agreement

BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of a new 15-year lease with Omeros Corporation (NASDAQ: OMER) for BioMed's Waterfront Research Center property located in Seattle, Washington.  A clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system, Omeros will relocate and consolidate their corporate headquarters and primary research facilities into approximately 64,500 square feet of laboratory and office space at the recently redeveloped five-story life science building located at 201 Elliott Avenue West, in the heart of Seattle's scientific community. The property, which has been renamed "The Omeros Building," is in close proximity to Amgen's campus, the Fred Hutchinson Cancer Research Center and the new home of the Bill and Melinda Gates Foundation. Omeros expects to move into The Omeros Building in the fall of this year.

"This is an ideal location for us to consolidate our corporate headquarters and research facilities," said Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer of Omeros.  "We are pleased with BioMed's willingness to provide us with a lease that will help us address our current and future facility needs while reducing our overhead costs for the next several years. With their specialized experience in our industry, we look forward to building a strong relationship with BioMed and appreciate their long-term commitment to Omeros."

Alan D. Gold, Chairman and Chief Executive Officer of BioMed, added, "We are very excited to introduce Omeros as the anchor tenant at The Omeros Building. This building will provide Omeros with new corporate offices and state-of-the-art laboratories that will be important assets in the continuing advancement of Omeros' pipeline. We are very impressed with Omeros' programs and prospects, and we look forward to working as a partner to help Omeros achieve their long-term goals."